Search This Blog

Friday, July 31, 2020

FDA OKs Roche triplet therapy for certain type of melanoma

July 31, 2020

Under Priority Review status, the FDA approves Roche’s (OTCQX:RHHBY) triplet therapy of Tecentriq (atezolizumab), Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma.
This is an example of the “cocktail” approach to treating cancer with drugs with different mechanisms of action. Atezolizumab is a PD-L1 blocker and cobimetinib and vemurafenib are kinase inhibitors.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.